General Information of Drug Combination (ID: DC15JJC)

Drug Combination Name
Dopamine Alprostadil
Indication
Disease Entry Status REF
Children AKI Patients Phase 4 [1]
Component Drugs Dopamine   DMPGUCF Alprostadil   DMWH7NQ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Dopamine
Disease Entry ICD 11 Status REF
Acromegaly 5A60.0 Approved [2]
Carcinoid syndrome 5B10 Approved [2]
Parkinson disease 8A00.0 Approved [3]
Parkinsonian disorder N.A. Approved [2]
Postencephalitic Parkinson disease N.A. Approved [2]
Hypotension BA20-BA21 Phase 1 [3]
Dopamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Agonist [10]
------------------------------------------------------------------------------------
Dopamine Interacts with 6 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [11]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [12]
Vesicular amine transporter 2 (SLC18A2) DTT7VPB VMAT2_HUMAN Substrate [13]
Vesicular amine transporter 1 (SLC18A1) DTM953D VMAT1_HUMAN Substrate [13]
Synaptic vesicle glycoprotein 2C (SLC22B3) DT7A9GF SV2C_HUMAN Substrate [14]
Sodium-dependent dopamine transporter (SLC6A3) DT3BA8L SC6A3_HUMAN Substrate [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DTP(s)
Dopamine Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [16]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [17]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [17]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [17]
Catechol O-methyltransferase (COMT) DEV3T4A COMT_HUMAN Metabolism [18]
Monoamine oxidase type B (MAO-B) DET2NXO AOFB_HUMAN Metabolism [19]
Sulfotransferase 1B1 (SULT1B1) DED5UR3 ST1B1_HUMAN Metabolism [20]
Dopamine dehydroxylase (dadH) DEL0D64 DADH_EGGLN Metabolism [21]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Dopamine Interacts with 41 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Sodium-dependent dopamine transporter (SLC6A3) OT39XG28 SC6A3_HUMAN Increases Activity [22]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Increases ADR [23]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Increases Expression [24]
Bcl-2-binding component 3, isoforms 3/4 (BBC3) OTUAXDAY BBC3B_HUMAN Increases Expression [24]
POTE ankyrin domain family member F (POTEF) OTV3WXYE POTEF_HUMAN Increases Expression [7]
Citrate synthase, mitochondrial (CS) OTYLYXMO CISY_HUMAN Increases Expression [7]
ATP synthase subunit d, mitochondrial (ATP5PD) OTAJDLE2 ATP5H_HUMAN Increases Expression [7]
Prelamin-A/C (LMNA) OT3SG7ZR LMNA_HUMAN Increases Expression [7]
Fructose-bisphosphate aldolase A (ALDOA) OTWRFTIB ALDOA_HUMAN Increases Expression [7]
ADP/ATP translocase 2 (SLC25A5) OT1XIBMN ADT2_HUMAN Increases Expression [7]
Heat shock protein HSP 90-beta (HSP90AB1) OTR69EG7 HS90B_HUMAN Increases Expression [7]
Small ribosomal subunit protein uS2 (RPSA) OTJZHEGT RSSA_HUMAN Increases Expression [7]
POTE ankyrin domain family member I (POTEI) OTST4AVP POTEI_HUMAN Decreases Expression [7]
ADP/ATP translocase 3 (SLC25A6) OT9KAJP7 ADT3_HUMAN Increases Expression [7]
Annexin A3 (ANXA3) OTDD8OI7 ANXA3_HUMAN Increases Expression [7]
Histone H1.5 (H1-5) OTAN7RD9 H15_HUMAN Increases Expression [7]
Heat shock 70 kDa protein 6 (HSPA6) OTH4S7WB HSP76_HUMAN Increases Expression [7]
Cofilin-1 (CFL1) OTT6D5MH COF1_HUMAN Increases Expression [7]
Thioredoxin-dependent peroxide reductase, mitochondrial (PRDX3) OTLB2WEU PRDX3_HUMAN Increases Expression [7]
Protein disulfide-isomerase A3 (PDIA3) OTHPQ0Q3 PDIA3_HUMAN Decreases Expression [7]
Serine hydroxymethyltransferase, mitochondrial (SHMT2) OT5NCAZN GLYM_HUMAN Increases Expression [7]
Stress-70 protein, mitochondrial (HSPA9) OT4TMVS9 GRP75_HUMAN Increases Expression [7]
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Affects Expression [7]
Small ribosomal subunit protein RACK1 (RACK1) OTZBCQ1U RACK1_HUMAN Increases Expression [7]
Elongation factor 1-alpha 1 (EEF1A1) OT00THXS EF1A1_HUMAN Increases Expression [7]
Single-stranded DNA-binding protein, mitochondrial (SSBP1) OTH2PZWH SSBP_HUMAN Increases Expression [7]
Complement component 1 Q subcomponent-binding protein, mitochondrial (C1QBP) OTPYQX3K C1QBP_HUMAN Increases Expression [7]
Beta-actin-like protein 2 (ACTBL2) OTD6B81U ACTBL_HUMAN Decreases Expression [7]
5'-3' exonuclease PLD3 (PLD3) OTL07SP2 PLD3_HUMAN Affects Expression [7]
Septin-9 (SEPTIN9) OT1VMRFQ SEPT9_HUMAN Decreases Expression [7]
RuvB-like 1 (RUVBL1) OTWV19L7 RUVB1_HUMAN Increases Expression [7]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Increases Expression [25]
Brain mitochondrial carrier protein 1 (SLC25A14) OT1ZQSKS UCP5_HUMAN Increases Expression [26]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Phosphorylation [27]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [27]
D(1A) dopamine receptor (DRD1) OTLZPBT7 DRD1_HUMAN Increases Activity [28]
Protein-L-isoaspartate(D-aspartate) O-methyltransferase (PCMT1) OTGYVSGU PIMT_HUMAN Decreases Expression [29]
Alpha-synuclein (SNCA) OTPWC1MR SYUA_HUMAN Increases Response To Substance [30]
Solute carrier family 22 member 3 (SLC22A3) OTQYGVXX S22A3_HUMAN Increases Uptake [31]
Secretin (SCT) OTV3MLOO SECR_HUMAN Increases Metabolism [32]
Equilibrative nucleoside transporter 4 (SLC29A4) OTWTZXMX S29A4_HUMAN Increases Uptake [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 41 DOT(s)
Indication(s) of Alprostadil
Disease Entry ICD 11 Status REF
Aorta coarctation N.A. Approved [4]
Diabetic foot ulcer BD54 Approved [5]
Erectile dysfunction HA01.1 Approved [6]
Pulmonary hypertension BB01 Approved [4]
Tetralogy of fallot N.A. Approved [4]
Alprostadil Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Agonist [5]
Thromboxane A2 receptor (TBXA2R) TT2O84V TA2R_HUMAN Modulator [34]
------------------------------------------------------------------------------------
Alprostadil Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [35]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [36]
Organic anion transporting polypeptide 2A1 (SLCO2A1) DT021JD SO2A1_HUMAN Substrate [37]
Organic anion transporting polypeptide 3A1 (SLCO3A1) DTVNRXW SO3A1_HUMAN Substrate [38]
------------------------------------------------------------------------------------
Alprostadil Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Prostaglandin dehydrogenase 1 (HPGD) DEHKSC6 PGDH_HUMAN Metabolism [39]
------------------------------------------------------------------------------------
Alprostadil Interacts with 4 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Renin (REN) OT52GZR2 RENI_HUMAN Increases Expression [40]
Natriuretic peptides A (NPPA) OTMQNTNX ANF_HUMAN Decreases Expression [41]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Increases Phosphorylation [42]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Decreases Expression [43]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03892447) The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury
2 Dopamine FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 940).
4 Alprostadil FDA Label
5 Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1882).
7 Mitochondrial proteomics investigation of a cellular model of impaired dopamine homeostasis, an early step in Parkinson's disease pathogenesis. Mol Biosyst. 2014 Jun;10(6):1332-44.
8 Vitamin D signaling and the differentiation of developing dopamine systems. Neuroscience. 2016 Oct 1;333:193-203. doi: 10.1016/j.neuroscience.2016.07.020. Epub 2016 Jul 20.
9 Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Mol Psychiatry. 2011 Sep;16(9):927-37, 881. doi: 10.1038/mp.2011.32. Epub 2011 Apr 19.
10 The Detection of Dopamine Gene Receptors (DRD1-DRD5) Expression on Human Peripheral Blood Lymphocytes by Real Time PCR. Iran J Allergy Asthma Immunol. 2004 Dec;3(4):169-74.
11 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
12 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
13 SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013 Apr-Jun;34(2-3):360-72.
14 Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease. Proc Natl Acad Sci U S A. 2017 Mar 14;114(11):E2253-E2262.
15 Characterization of VNTRs Within the Entire Region of SLC6A3 and Its Association with Hypertension. DNA Cell Biol. 2017 Mar;36(3):227-236.
16 Modulation of CYP1A2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine. Pharmacogenetics. 1998 Jun;8(3):251-8.
17 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
18 Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60.
19 Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011 Jul;1813(7):1323-32.
20 Molecular cloning, expression, and functional characterization of novel mouse sulfotransferases. Biochem Biophys Res Commun. 1998 Jun 29;247(3):681-6.
21 Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445). pii: eaau6323.
22 Functional characterization of N-octyl 4-methylamphetamine variants and related bivalent compounds at the dopamine and serotonin transporters using Ca(2+) channels as sensors. Toxicol Appl Pharmacol. 2021 May 15;419:115513. doi: 10.1016/j.taap.2021.115513. Epub 2021 Mar 27.
23 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
24 Effects of dopamine on LC3-II activation as a marker of autophagy in a neuroblastoma cell model. Neurotoxicology. 2009 Jul;30(4):658-65. doi: 10.1016/j.neuro.2009.04.007. Epub 2009 May 4.
25 Induction of parkin expression in the presence of oxidative stress. Eur J Neurosci. 2006 Sep;24(5):1366-72. doi: 10.1111/j.1460-9568.2006.04998.x.
26 Mitochondrial UCP5 is neuroprotective by preserving mitochondrial membrane potential, ATP levels, and reducing oxidative stress in MPP+ and dopamine toxicity. Free Radic Biol Med. 2010 Sep 15;49(6):1023-35. doi: 10.1016/j.freeradbiomed.2010.06.017. Epub 2010 Jun 19.
27 Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet. 2004 Aug 15;13(16):1745-54. doi: 10.1093/hmg/ddh180. Epub 2004 Jun 15.
28 Characterizing fucoxanthin as a selective dopamine D(3)/D(4) receptor agonist: Relevance to Parkinson's disease. Chem Biol Interact. 2019 Sep 1;310:108757. doi: 10.1016/j.cbi.2019.108757. Epub 2019 Jul 16.
29 Dopamine down-regulation of protein L-isoaspartyl methyltransferase is dependent on reactive oxygen species in SH-SY5Y cells. Neuroscience. 2014 May 16;267:263-76. doi: 10.1016/j.neuroscience.2014.03.001. Epub 2014 Mar 12.
30 G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage. Neurochem Int. 2004 Oct;45(5):669-76. doi: 10.1016/j.neuint.2004.03.029.
31 Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3. J Pharmacol Exp Ther. 2010 Dec;335(3):743-53. doi: 10.1124/jpet.110.170142. Epub 2010 Sep 21.
32 Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006 Mar;28(2):99-103. doi: 10.1016/j.braindev.2005.05.005. Epub 2005 Sep 15.
33 Arsenic trioxide-mediated antiplatelet activity: pivotal role of the phospholipase C gamma 2-protein kinase C-p38 MAPK cascade. Transl Res. 2010 Feb;155(2):97-108. doi: 10.1016/j.trsl.2009.08.005. Epub 2009 Sep 15.
34 Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
35 The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9.
36 Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7.
37 Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9.
38 Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97.
39 Effect of calcium ionophore A23187 on prostaglandin synthase type 2 and 15-hydroxy-prostaglandin dehydrogenase expression in human chorion trophoblast cells. Am J Obstet Gynecol. 2008 Nov;199(5):554.e1-8.
40 Catecholamine and renin-angiotensin response during controlled hypotension induced by prostaglandin E1 combined with hemodilution during isoflurane anesthesia. J Clin Anesth. 1997 Jun;9(4):321-7. doi: 10.1016/s0952-8180(97)00011-1.
41 Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Jpn Heart J. 1999 May;40(3):321-34. doi: 10.1536/jhj.40.321.
42 Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies. Mol Pharmacol. 2004 Jan;65(1):196-206. doi: 10.1124/mol.65.1.196.
43 Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure. Eur J Heart Fail. 2005 Dec;7(7):1156-63. doi: 10.1016/j.ejheart.2005.05.001. Epub 2005 Aug 5.